NOXOPHARM LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.072 AUD | -7.69% |
|
+14.29% | +1.41% |
| Apr. 04 | Noxopharm Receives AU$100,000 to Progress Brain Cancer Drug | MT |
| Feb. 27 | Noxopharm Narrows Fiscal H1 Net Loss Despite Lower R&D Tax Incentive | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 5.43M 3.63M | Sales 2023 | 6.01M 4.02M | Capitalization | 12.57M 8.41M |
|---|---|---|---|---|---|
| Net income 2022 | -18M -12.05M | Net income 2023 | -15M -10.04M | EV / Sales 2022 | 7.95 x |
| Net cash position 2022 | 13.85M 9.27M | Net cash position 2023 | 3.01M 2.01M | EV / Sales 2023 | 1.59 x |
| P/E ratio 2022 |
-3.04
x | P/E ratio 2023 |
-0.83
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 64.79% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -7.69% | ||
| 1 week | +14.29% | ||
| Current month | +7.46% | ||
| 1 month | +16.13% | ||
| 3 months | +20.00% | ||
| 6 months | -46.67% | ||
| Current year | +1.41% |
1 week
0.06
0.08
1 month
0.060.08
Current year
0.050.11
1 year
0.030.17
3 years
0.030.81
5 years
0.030.99
10 years
0.031.80
| Managers | Title | Age | Since |
|---|---|---|---|
Gisela Mautner
CEO | Chief Executive Officer | - | - |
| Director of Finance/CFO | - | 19-02-28 | |
Olivier Laczka
CTO | Chief Tech/Sci/R&D Officer | - | 19-10-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Fred Bart
CHM | Chairman | 69 | 20-05-07 |
Peter Marks
BRD | Director/Board Member | 68 | 16-03-14 |
Boris Patkin
BRD | Director/Board Member | - | 20-03-25 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 0.072 | -7.69% | 665,965 |
| 24-05-15 | 0.078 | +14.71% | 452,444 |
| 24-05-14 | 0.068 | +7.94% | 259,868 |
| 24-05-13 | 0.063 | 0.00% | 175,209 |
| 24-05-10 | 0.063 | +5.00% | 72,785 |
Delayed Quote Australian S.E., May 17, 2024 at 01:56 am EDT
More quotes
Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.
Sector
Pharmaceuticals
Calendar
2024-08-28
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +1.41% | 14.06M | |
| -2.32% | 90.45B | |
| +3.68% | 41.45B | |
| -10.90% | 33.57B | |
| +58.05% | 25.73B | |
| -19.56% | 14.73B | |
| -9.06% | 12.82B | |
| -11.34% | 11.7B | |
| -43.53% | 11.44B | |
| +3.75% | 8.79B |
- Stock Market
- Equities
- NOX Stock
